GLP-1 Drugs Could Reach 21% of U.S. Adults by 2030, Reshaping Daily Life
Updated
Updated · Psychology Today · Jul 30
GLP-1 Drugs Could Reach 21% of U.S. Adults by 2030, Reshaping Daily Life
1 articles · Updated · Psychology Today · Jul 30
Summary
13% to 21% of U.S. adults—about 30 million to 50 million people—could be using GLP-1 medicines within several years, extending their impact far beyond weight loss.
11% of U.S. adults were taking a GLP-1 for weight loss in 2026, up from 3% in 2024, while 15% say they have used one at some point.
Consumer habits are already shifting: studies and anecdotal evidence point to more produce and lean-protein purchases, smaller apparel sizes, resale growth for discarded clothes, and potential airline fuel savings from lower passenger weight.
Social effects may spread next, with thinner bodies losing status value as prescriptions widen access, dating norms adapting to GLP-1 disclosure, and older adults gaining mobility in retirement.
Healthcare and family impacts could prove uneven—boutique care may widen outcome gaps, unplanned 'Ozempic babies' are already being noted, and adolescent use has risen roughly sixfold in five years.